Table 3.

Adjusted ORs for BMI among colorectal adenoma cases, colonoscopy controls, and population controls; Minnesota Cancer Prevention Unit Case-Control Study, 1991-1994

BMI* (kg/m2)Colonoscopy controls
Population controls
Cases (n)Controls (n)OR (95% CI)PheterogeneityCases (n)Controls (n)OR (95% CI)Pheterogeneity
All women
    <25.0 (reference)931721.00 (—)0.72931271.00 (—)0.28
    25.0-<30.0641310.87 (0.58-1.31)64631.27 (0.80-2.00)
    ≥30.045880.85 (0.54-1.35)45431.49 (0.89-2.49)
Premenopausal women
    <25.0 (reference)17681.00 (—)0.2017371.00 (—)0.05
    25.0-<30.07390.81 (0.30-2.25)7101.61 (0.40-6.50)
    ≥30.011212.09 (0.81-5.41)1185.18 (1.40-19.32)
Postmenopausal women
    <25.0 (reference)751041.00 (—)0.2075901.00 (—)0.90
    25.0-<30.056920.86 (0.54-1.37)56531.12 (0.67-1.86)
    ≥30.034690.61 (0.36-1.05)34351.01 (0.55-1.84)
Postmenopausal PMH users
    <25.0 (reference)42671.00 (—)0.0242581.00 (—)0.68
    25.0-<30.024620.65 (0.35-1.22)24251.03 (0.49-2.13)
    ≥30.08410.29 (0.12-0.70)8130.64 (0.23-1.83)
Postmenopausal PMH nonusers
    <25.0 (reference)35371.00 (—)0.8835321.00 (—)0.87
    25.0-<30.034301.19 (0.60-2.38)34281.19 (0.59-2.41)
    ≥30.026281.05 (0.50-2.17)26221.19 (0.56-2.54)
  • NOTE: ORs were adjusted for age, family history of colon cancer, family history of polyps, and pack-years of smoking.

  • * Categories based on WHO cutoff points.

  • Breslow-Day test for heterogeneity of ORs.

  • Additionally adjusted for PMH use.